WO2010045379A3 - Pyridine non-classical cannabinoid compounds and related methods of use - Google Patents

Pyridine non-classical cannabinoid compounds and related methods of use Download PDF

Info

Publication number
WO2010045379A3
WO2010045379A3 PCT/US2009/060706 US2009060706W WO2010045379A3 WO 2010045379 A3 WO2010045379 A3 WO 2010045379A3 US 2009060706 W US2009060706 W US 2009060706W WO 2010045379 A3 WO2010045379 A3 WO 2010045379A3
Authority
WO
WIPO (PCT)
Prior art keywords
related methods
cannabinoid compounds
classical cannabinoid
pyridine
pyridine non
Prior art date
Application number
PCT/US2009/060706
Other languages
French (fr)
Other versions
WO2010045379A2 (en
Inventor
Steven Gurley
Suni Mustafa
Bob M Moore
Original Assignee
University Of Tennessee Research Foundation, The
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University Of Tennessee Research Foundation, The filed Critical University Of Tennessee Research Foundation, The
Publication of WO2010045379A2 publication Critical patent/WO2010045379A2/en
Publication of WO2010045379A3 publication Critical patent/WO2010045379A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/69—Two or more oxygen atoms

Abstract

Disclosed are compounds of the formula (I): wherein R1, R2, V, W, X, Y and Z can be as defined herein. The compounds can be used in the treatment of disorders mediated by the cannabinoid receptors.
PCT/US2009/060706 2008-10-14 2009-10-14 Pyridine non-classical cannabinoid compounds and related methods of use WO2010045379A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10514308P 2008-10-14 2008-10-14
US61/105,143 2008-10-14

Publications (2)

Publication Number Publication Date
WO2010045379A2 WO2010045379A2 (en) 2010-04-22
WO2010045379A3 true WO2010045379A3 (en) 2010-07-22

Family

ID=42107216

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2009/060706 WO2010045379A2 (en) 2008-10-14 2009-10-14 Pyridine non-classical cannabinoid compounds and related methods of use

Country Status (1)

Country Link
WO (1) WO2010045379A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2684879A1 (en) 2012-07-09 2014-01-15 Basf Se Substituted mesoionic compounds for combating animal pests

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH11140055A (en) * 1997-09-01 1999-05-25 Nissan Chem Ind Ltd 6-haloalkyl-3-substituted phenyl-2(1h)-pyridinone derivative and herbicide
US20050159449A1 (en) * 2002-04-25 2005-07-21 Virginia Commonwealth University Cannabinoids
US20070135388A1 (en) * 2001-07-13 2007-06-14 Alexandros Makriyannis Novel Bicyclic Cannabinoids
WO2008013963A2 (en) * 2006-07-28 2008-01-31 University Of Connecticut Fatty acid amide hydrolase inhibitors

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH11140055A (en) * 1997-09-01 1999-05-25 Nissan Chem Ind Ltd 6-haloalkyl-3-substituted phenyl-2(1h)-pyridinone derivative and herbicide
US20070135388A1 (en) * 2001-07-13 2007-06-14 Alexandros Makriyannis Novel Bicyclic Cannabinoids
US20050159449A1 (en) * 2002-04-25 2005-07-21 Virginia Commonwealth University Cannabinoids
WO2008013963A2 (en) * 2006-07-28 2008-01-31 University Of Connecticut Fatty acid amide hydrolase inhibitors

Also Published As

Publication number Publication date
WO2010045379A2 (en) 2010-04-22

Similar Documents

Publication Publication Date Title
WO2008030367A3 (en) Selective myostatin inhibitors
WO2010004197A3 (en) Pyridino-pyridinone derivatives, preparation thereof, and therapeutic use thereof
WO2010033543A3 (en) Substituted benzamides as cannabinoid receptor ligands
WO2010037054A3 (en) Heteroaryl antagonists of prostaglandin d2 receptors
WO2010071783A8 (en) Thiazoles as cannabinoid receptor ligands
WO2008128072A3 (en) Axl kinase inhibitors useful for the treatment of cancer or hyperproliferative disorders
WO2008104306A3 (en) Substituted 4-aryl-1,4-dihydro-1,6-naphthyridinamides and use thereof
WO2004022537A3 (en) Thienopyrrolyl and furanopyrrolyl compounds and their use as histamine h4 receptor ligands
WO2010057118A3 (en) Heterocyclic antagonists of prostaglandin d2 receptors
WO2010003120A3 (en) Antagonists of prostaglandin d2 receptors
WO2009077471A3 (en) Azolylmethyloxiranes, use thereof and agents containing the same
WO2009087098A3 (en) Quinoline derivatives and their use as fungicides
WO2009117676A3 (en) Novel piperidine derivatives as inhibitors of stearoyl-coa desaturase
WO2009108720A3 (en) Antagonists of prostaglandin d2 receptors
WO2008130953A3 (en) 2-imin0is0thiaz0le derivatives as cannabinoid receptor ligands
MX2010007392A (en) Trpa1 antagonists.
WO2006066950A3 (en) Tricyclic aminoalcohols, methods for producing the same and their use as anti-inflammatory agents
WO2010028338A3 (en) Novel compounds as cannabinoid receptor ligands
WO2009015037A3 (en) 5-pyridinone substituted indazoles
WO2008083950A8 (en) Spirocyclic tetronic acid derivatives
WO2008027600A3 (en) Imatinib compositions
MY147649A (en) Benzimidazole derivatives useful in treatment of vallinoid receptor trpv1 related disorders
TW200942530A (en) Pyridine compounds
WO2010054024A3 (en) 1, 2 -thiazol yl derivatives as cannabinoid receptor ligands
GB0822158D0 (en) Method,composition and device for the treatment of enzymes and saccharides disorders

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09821211

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09821211

Country of ref document: EP

Kind code of ref document: A2